SLXN
Silexion Therapeutics Corp
$0.5298
+96.95%
$1.1M
No data for this timeframe.
Vol
Market Cap$1.1M
Cap SizeNano Cap
Insider Activity0B / 1S
Insider Net $-$31.0K
Reddit Sentiment50° Neutral
SEC Reports1
Press Releases7
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. E9·CIK 0002022416·Prev Close $0.2690
Recent Activity
May 18, 2026
Press
Silexion received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in locally advanced pancre
Impact 7/10
May 18, 2026
fda
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><i>Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clin
May 15, 2026
Press
Silexion Therapeutics entered into warrant exercise agreements to raise ~$1M in gross proceeds, issuing new Series C and
Impact 7/10
Mar 26, 2026
Insider
Shirvan Mitchell sold 22,818 shares
CSO and CDO @ $1.36 ($31.0K)
Mar 16, 2026
SEC
Silexion Therapeutics is holding an extraordinary general meeting to vote on two proposals: increasing authorized share
DEFA14A — Impact 4/10
Feb 20, 2026
Insider
Noy Shlomo sold 10,685 shares
Director @ $0.00 ($0.00)
Feb 20, 2026
Insider
Noy Shlomo sold 9,091 shares
Director @ $0.00 ($0.00)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$6.00 (Dec 2025)
Current $0.5298
Low $6.00
Median $6.00
High $6.00
2 analysts
$6.00
$6.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 15, 2025 | Litchfield Hills | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.31 | $-1.31 — $-1.31 | 1 | |
| Next Q | $-1.33 | $-1.33 — $-1.33 | 54% YoY | 1 |
| Current FY | $-4.12 ▲ +6.3% | $-4.55 — $-3.69 | 54% YoY | 2 |
| Next FY | $-2.87 ▲ +34.4% | $-3.50 — $-2.23 | 30% YoY | 2 |
Latest Reports
BULLISH
Press
7/10
Silexion received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in locally advanced pancre
May 18, 2026
NEUTRAL
DEFA14A
4/10
Silexion Therapeutics is holding an extraordinary general meeting to vote on two proposals: increasing authorized share
Mar 16, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 26, 2026 | Shirvan Mitchell | SELL | $31.0K |
| Feb 20, 2026 | Noy Shlomo | A | $0.00 |
| Feb 20, 2026 | Noy Shlomo | A | $0.00 |
| Feb 20, 2026 | Alon Ruth | A | $0.00 |
| Feb 20, 2026 | Alon Ruth | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
8 unique insiders with 1 transactions. Net insider value: -$31.0K ($0.00 bought, $31.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | Shirvan Mitchell | CSO and CDO | SELL | 22,818 | $1.36 | $31.0K |
| Feb 20, 2026 | Noy Shlomo | Director | A | 10,685 | $0.00 | $0.00 |
| Feb 20, 2026 | Noy Shlomo | Director | A | 9,091 | $0.00 | $0.00 |
| Feb 20, 2026 | Alon Ruth | Director | A | 9,091 | $0.00 | $0.00 |
| Feb 20, 2026 | Alon Ruth | Director | A | 10,685 | $0.00 | $0.00 |
| Feb 20, 2026 | Shirvan Mitchell | CSO and CDO | A | 49,726 | $0.00 | $0.00 |
| Feb 20, 2026 | Horenshtein Hadar Mirit | CFO and Secretary | A | 49,726 | $0.00 | $0.00 |
| Feb 20, 2026 | Hadar Ilan | Chairman and CEO | A | 64,350 | $0.00 | $0.00 |
| Feb 20, 2026 | Peled Amnon | Director | A | 7,576 | $0.00 | $0.00 |
| Feb 20, 2026 | Peled Amnon | Director | A | 8,904 | $0.00 | $0.00 |
| Feb 20, 2026 | Lushi Avner | Director | A | 9,091 | $0.00 | $0.00 |
| Feb 20, 2026 | Lushi Avner | Director | A | 10,685 | $0.00 | $0.00 |
| Feb 20, 2026 | Abramov Dror Yosef | Director | A | 9,091 | $0.00 | $0.00 |
| Feb 20, 2026 | Abramov Dror Yosef | Director | A | 10,685 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
BULLISH
7/10
Silexion received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in loc
May 18, 2026
BEARISH
7/10
Silexion Therapeutics entered into warrant exercise agreements to raise ~$1M in gross proceeds, issu
May 15, 2026
NEUTRAL
4/10
Silexion Therapeutics reported positive preclinical data showing its siRNA candidate SIL204 increase
May 14, 2026
BULLISH
5/10
Silexion Therapeutics announced initiation of GMP manufacturing of SIL204 with Catalent and ethics c
May 13, 2026
BULLISH
8/10
Silexion Therapeutics has received approval from the Israeli Ministry of Health to initiate a Phase
Mar 24, 2026
BULLISH
8/10
Silexion Therapeutics received formal approval from the Israeli Ministry of Health to initiate a Pha
Mar 24, 2026
MIXED
6/10
Silexion Therapeutics reported financial results for 2025, showing a reduced annual net loss of $11.
Mar 17, 2026
Historical analyst distribution (last covering-analyst action Dec 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$6.00 mean target (Dec 2025)
$6.00 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $0.5298 |
| Target Low | $6.00 |
| Target Mean | $6.00 |
| Target Median | $6.00 |
| Target High | $6.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.31 | $-1.31 | $-1.31 | — | — | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-1.33 | $-1.33 | $-1.33 | 53.8% | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-4.12 | $-4.55 | $-3.69 | 54.0% | +6.3% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-2.87 | $-3.50 | $-2.23 | 30.5% | +34.4% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.310 | |
| 7d ago | $0.000 | -1.310 |
| 30d ago | $0.000 | -1.310 |
| 60d ago | $0.000 | -1.310 |
| 90d ago | $0.000 | -1.310 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 15, 2025 | Litchfield Hills | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 18, 2026
fda
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><i>Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreati
May 15, 2026
fda
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
<p align="justify">Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinic
May 14, 2026
fda
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human p
May 13, 2026
fda
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
<p align="center"><i>Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collabo
Mar 24, 2026
fda
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
<p align="center"><i>Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an i
Mar 24, 2026
fda
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
<p align="center"><i>Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an i
Mar 17, 2026
earnings
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p align="center"><i>Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and fo